Skip to Content
Søk Menu

ASH | American Society of Hematology Meeting & Exposition

ASH 2023

Jason Westin

Potential for Targeted and Immune-Facing Therapies for Patients with CNS Lymphoma

/ Jason Westin
ASH23Lymfom Play the Video

MEDtalks från ASH 2023

ASH 2023: The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated CLL

/ Hematologi / BestPractice Nordic

ASH 2023: FDA Approves Gene Therapies for Sickle Cell Disease

/ Hematologi / BestPractice Nordic

ASH 2023: ELEVATE-TN Study – 6-Year Follow-up of Acalabrutinib Efficacy in CLL

/ Hematologi / BestPractice Nordic

ASH 2023: CAPTIVATE Study – Ibrutinib-Venetoclax for CLL/SLL

/ Hematologi / BestPractice Nordic

ASH 2023: Oral Decitabine-Cedazuridine Tablet Shows Promise for AML Treatment in Phase III Study

/ Hematologi / BestPractice Nordic

Don’t Miss Out on ASH 2023 

/ Hematologi / BestPractice Nordic

MRD Status in NPM1 Mutated AML Should Be a Part of the Selection of Patients for Transplant in First Remission

/ Hematologi / Jad Othman

Chemotherapy Might Not Be Needed in Frontline Treatment of Patients with Large B-Cell Lymphoma

/ Hematologi / Jason Westin

Undiagnosed and Unrecognized Patients with a High Bleeding Score

/ Hematologi / Eva Birgitte Leinøe

A Potential New Standard of Care for Transplant-Eligible Patients with Multiple Myeloma

/ Hematologi / Pieter Sonneveld

No increase risk of Ventricular Arrhythmias and Sudden Death with Acalabrutinib

/ Hematologi / Jeff P. Sharman

Hematology 2023

  • Meet the experts
  • 2023
Få tillgang

Mer från ASH 2023

Gabriel Brisou

Real World Data of Axicabtagene Ciloleucel As Second Line Therapy for Patients with Large B-Cell Lymphoma

/ Gabriel Brisou
ASH23B-celle lymfom Play the Video
Hamish Scott & Chris Hahn

ERG deficiency syndrome – maybe a new disease

/ Hamish S. Scott / Christopher Hahn
ASH23 Play the Video
Jeff P. Sharman

Acalabrutinib in Frontline CLL Treatment: Six-Year Results from the Elevate-TN Study

/ Jeff P. Sharman
ASH23CLL Play the Video
Amer Zeidan

New Data on Oral Decitabine in MDS: Real-Life Analysis and Outcomes from ASH2023

/ Amer Zeidan
ASH23 Play the Video
Mats Jerkeman

Key Updates in Mantle Cell Lymphoma from ASH 2023

/ Mats Jerkeman
ASH23Lymfom Play the Video
Mats Jerkeman

CAR-T Cell Therapy as Second-Line Treatment for Elderly Patients with Relapsed/Refractory Large B-Cell Lymphoma

/ Mats Jerkeman
ASH23B-celle lymfom Play the Video
Peter Hillmen

New Standard of Care for Previously Untreated CLL

/ Peter Hillmen
ASH23CLL Play the Video

ASH2023 AI in Hematology: Enhancing Diagnostic Precision for Two Rare Blood Cancers

/ Andrew Srisuwananukorn
AIASH23 Play the Video
Jelena Jelicic

Advancing Prognostic Models in Diffuse Large B-Cell Lymphoma Treatment

/ Jelena Jelicic
ASH23B-celle lymfom Play the Video
Banu Aygun

REACH Study: Hydroxyurea’s 7-8 Year Impact on 600 African Children with Sickle Cell Anemia

/ Banu Aygun
ASH23BarnBehandling Play the Video
Paolo Ghia

CAPTIVATE Study: CLL Combination Therapy of Ibrutinib and Venetoclax

/ Paolo Ghia
ASH23CLL Play the Video
Fabian Mueller

CD19 CAR T-Cell Therapy: A New Frontier in Autoimmune Disease Remission

/ Fabian Mueller
ASH23Cart-T Play the Video
Load more

EHA | Kongress

Vi publicerar de viktigaste höjdpunkterna från EHA i form av sammanfattningar, onlineartiklar, MEDtalks med internationella och nationella specialister.

Se allt innehåll

Onkologi / Hematologi • Nr. 1 • 2023

  • Breast Cancer Focus
  • ESMO & Norsk Aften 2023
  • The Link Between Breast Cancer and Hematologic Cancers
Få tillgang

ASh 2022

Updated results on AVO therapeutic triplet regimen in untreated patients with CLL

/ Christine Ryan
ASH22KLL Play the Video

Treatment Options for FLT3 mutant acute myeloid leukemia

/ Eunice Wang
AMLASH22 Play the Video

Significant longer PFS among patients who received zanubrutinib vs ibrutinib

/ Jennifer R. Brown
ASH22KLL Play the Video

Venetoclax plus obinutuzumab er den mest omkostningseffektive behandling af CLL uden del17p/TP53-mutationer

/ Matilde Slot
ASH22KLL Play the Video

Several interesting combinations of therapies with Calquence for patients with CLL

/ Matthew S. Davids
ASH22KLL Play the Video

New combination shows promising efficacy in patients with triple-class refractory R/R multiple myeloma

/ Paul G. Richardson
ASH22Myelom Play the Video

Lower-risk myelodysplastic syndromes treated with Reblozyl, luspatercept – Real-world outcomes

/ Sudipto Mukherjee
ASH22 Play the Video

LBA ASH22: Significantly better overall survival in patients with B-lineage ALL treated with Blincyto, blinatumomab, as Consolidation Therapy

/ Mark Robert Litzow
ALLASH22 Play the Video
Mer
Back to top